nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—ADRB2—polycystic ovary syndrome	0.756	1	CbGaD
Formoterol—Tonsillitis—Metformin—polycystic ovary syndrome	0.0106	0.127	CcSEcCtD
Formoterol—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0102	0.123	CcSEcCtD
Formoterol—Tooth abscess—Metformin—polycystic ovary syndrome	0.00639	0.077	CcSEcCtD
Formoterol—Fenoterol—ADRB3—polycystic ovary syndrome	0.00223	0.183	CrCbGaD
Formoterol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00213	0.0256	CcSEcCtD
Formoterol—Injury—Metformin—polycystic ovary syndrome	0.00211	0.0254	CcSEcCtD
Formoterol—Arbutamine—ADRB3—polycystic ovary syndrome	0.00208	0.171	CrCbGaD
Formoterol—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00198	0.0239	CcSEcCtD
Formoterol—Dehydration—Metformin—polycystic ovary syndrome	0.0018	0.0217	CcSEcCtD
Formoterol—Cramp muscle—Metformin—polycystic ovary syndrome	0.00174	0.021	CcSEcCtD
Formoterol—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00173	0.0209	CcSEcCtD
Formoterol—Influenza—Metformin—polycystic ovary syndrome	0.00167	0.0202	CcSEcCtD
Formoterol—Angina pectoris—Metformin—polycystic ovary syndrome	0.00163	0.0196	CcSEcCtD
Formoterol—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00156	0.0187	CcSEcCtD
Formoterol—Labetalol—ADRB3—polycystic ovary syndrome	0.00148	0.121	CrCbGaD
Formoterol—Rhinitis—Metformin—polycystic ovary syndrome	0.00134	0.0162	CcSEcCtD
Formoterol—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00132	0.0159	CcSEcCtD
Formoterol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00132	0.0159	CcSEcCtD
Formoterol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00124	0.015	CcSEcCtD
Formoterol—Immune system disorder—Metformin—polycystic ovary syndrome	0.00121	0.0146	CcSEcCtD
Formoterol—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00121	0.0146	CcSEcCtD
Formoterol—Malnutrition—Metformin—polycystic ovary syndrome	0.00117	0.0141	CcSEcCtD
Formoterol—Dysgeusia—Metformin—polycystic ovary syndrome	0.00114	0.0138	CcSEcCtD
Formoterol—Muscle spasms—Metformin—polycystic ovary syndrome	0.00112	0.0135	CcSEcCtD
Formoterol—Tremor—Metformin—polycystic ovary syndrome	0.00109	0.0132	CcSEcCtD
Formoterol—Isoprenaline—ADRB3—polycystic ovary syndrome	0.00109	0.0892	CrCbGaD
Formoterol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00108	0.013	CcSEcCtD
Formoterol—Malaise—Metformin—polycystic ovary syndrome	0.00105	0.0127	CcSEcCtD
Formoterol—Palpitations—Metformin—polycystic ovary syndrome	0.00103	0.0124	CcSEcCtD
Formoterol—Hypertension—Metformin—polycystic ovary syndrome	0.00101	0.0121	CcSEcCtD
Formoterol—Myalgia—Metformin—polycystic ovary syndrome	0.000993	0.012	CcSEcCtD
Formoterol—Chest pain—Metformin—polycystic ovary syndrome	0.000993	0.012	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000986	0.0119	CcSEcCtD
Formoterol—Discomfort—Metformin—polycystic ovary syndrome	0.000981	0.0118	CcSEcCtD
Formoterol—Oedema—Metformin—polycystic ovary syndrome	0.000952	0.0115	CcSEcCtD
Formoterol—Infection—Metformin—polycystic ovary syndrome	0.000945	0.0114	CcSEcCtD
Formoterol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000933	0.0112	CcSEcCtD
Formoterol—Skin disorder—Metformin—polycystic ovary syndrome	0.000924	0.0111	CcSEcCtD
Formoterol—Hypotension—Metformin—polycystic ovary syndrome	0.000889	0.0107	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000867	0.0105	CcSEcCtD
Formoterol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000848	0.0102	CcSEcCtD
Formoterol—Ritodrine—ADRB2—polycystic ovary syndrome	0.000847	0.0695	CrCbGaD
Formoterol—Fenoterol—ADRB2—polycystic ovary syndrome	0.000847	0.0695	CrCbGaD
Formoterol—Somnolence—Metformin—polycystic ovary syndrome	0.000846	0.0102	CcSEcCtD
Formoterol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000838	0.0101	CcSEcCtD
Formoterol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000822	0.0099	CcSEcCtD
Formoterol—Fatigue—Metformin—polycystic ovary syndrome	0.00082	0.00989	CcSEcCtD
Formoterol—Constipation—Metformin—polycystic ovary syndrome	0.000814	0.00981	CcSEcCtD
Formoterol—Arbutamine—ADRB2—polycystic ovary syndrome	0.000793	0.065	CrCbGaD
Formoterol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000784	0.00945	CcSEcCtD
Formoterol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000778	0.00938	CcSEcCtD
Formoterol—Arformoterol—ADRB2—polycystic ovary syndrome	0.000769	0.0631	CrCbGaD
Formoterol—Urticaria—Metformin—polycystic ovary syndrome	0.000756	0.00911	CcSEcCtD
Formoterol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000752	0.00907	CcSEcCtD
Formoterol—Dobutamine—ADRB2—polycystic ovary syndrome	0.000729	0.0598	CrCbGaD
Formoterol—Asthenia—Metformin—polycystic ovary syndrome	0.000683	0.00823	CcSEcCtD
Formoterol—Pruritus—Metformin—polycystic ovary syndrome	0.000673	0.00812	CcSEcCtD
Formoterol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000651	0.00785	CcSEcCtD
Formoterol—Dizziness—Metformin—polycystic ovary syndrome	0.000629	0.00758	CcSEcCtD
Formoterol—Vomiting—Metformin—polycystic ovary syndrome	0.000605	0.00729	CcSEcCtD
Formoterol—Rash—Metformin—polycystic ovary syndrome	0.0006	0.00723	CcSEcCtD
Formoterol—Dermatitis—Metformin—polycystic ovary syndrome	0.000599	0.00723	CcSEcCtD
Formoterol—Headache—Metformin—polycystic ovary syndrome	0.000596	0.00719	CcSEcCtD
Formoterol—Nausea—Metformin—polycystic ovary syndrome	0.000565	0.00681	CcSEcCtD
Formoterol—Labetalol—ADRB2—polycystic ovary syndrome	0.000562	0.0461	CrCbGaD
Formoterol—Isoprenaline—ADRB2—polycystic ovary syndrome	0.000414	0.0339	CrCbGaD
Formoterol—Isoprenaline—CYP1A1—polycystic ovary syndrome	0.000355	0.0291	CrCbGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	6.5e-05	0.000437	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	6.48e-05	0.000436	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SRD5A1—polycystic ovary syndrome	6.42e-05	0.000432	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	6.35e-05	0.000427	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	6.34e-05	0.000427	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.3e-05	0.000424	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	6.27e-05	0.000422	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—LPCAT2—polycystic ovary syndrome	6.23e-05	0.000419	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SUOX—polycystic ovary syndrome	6.23e-05	0.000419	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	6.21e-05	0.000418	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.17e-05	0.000415	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	6.15e-05	0.000414	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	6.14e-05	0.000413	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—STAR—polycystic ovary syndrome	6.12e-05	0.000412	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	6.01e-05	0.000404	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	5.93e-05	0.000399	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ISYNA1—polycystic ovary syndrome	5.79e-05	0.00039	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	5.79e-05	0.00039	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—POMC—polycystic ovary syndrome	5.78e-05	0.000389	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.74e-05	0.000386	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	5.73e-05	0.000386	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	5.73e-05	0.000386	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	5.68e-05	0.000382	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	5.68e-05	0.000382	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	5.66e-05	0.000381	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.61e-05	0.000378	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	5.61e-05	0.000377	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5.59e-05	0.000376	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5.47e-05	0.000368	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—HMMR—polycystic ovary syndrome	5.46e-05	0.000367	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	5.33e-05	0.000359	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	5.31e-05	0.000357	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	5.29e-05	0.000356	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	5.28e-05	0.000355	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	5.27e-05	0.000354	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	5.22e-05	0.000351	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—HSD3B1—polycystic ovary syndrome	5.21e-05	0.00035	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	5.16e-05	0.000347	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	5.11e-05	0.000344	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	5.11e-05	0.000344	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.08e-05	0.000342	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	5.02e-05	0.000337	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	5e-05	0.000337	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.97e-05	0.000334	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TEAD2—polycystic ovary syndrome	4.93e-05	0.000331	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKR1C2—polycystic ovary syndrome	4.93e-05	0.000331	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.91e-05	0.00033	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	4.82e-05	0.000324	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.8e-05	0.000323	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.78e-05	0.000321	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—LHB—polycystic ovary syndrome	4.75e-05	0.000319	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.74e-05	0.000319	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.67e-05	0.000314	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.66e-05	0.000314	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	4.66e-05	0.000313	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—HSD3B2—polycystic ovary syndrome	4.64e-05	0.000312	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	4.63e-05	0.000312	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.6e-05	0.000309	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	4.57e-05	0.000308	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	4.55e-05	0.000306	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	4.54e-05	0.000306	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	4.53e-05	0.000305	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	4.53e-05	0.000305	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.5e-05	0.000303	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—AKR1C1—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	4.49e-05	0.000302	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	4.45e-05	0.000299	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.44e-05	0.000299	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.34e-05	0.000292	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.32e-05	0.000291	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.3e-05	0.000289	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.29e-05	0.000289	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	4.26e-05	0.000287	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.25e-05	0.000286	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.21e-05	0.000283	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.2e-05	0.000283	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.2e-05	0.000283	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	4.17e-05	0.00028	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SULT2A1—polycystic ovary syndrome	4.14e-05	0.000278	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	4.13e-05	0.000278	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.06e-05	0.000273	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—RRM2—polycystic ovary syndrome	4.01e-05	0.00027	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	3.99e-05	0.000269	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.97e-05	0.000267	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	3.96e-05	0.000266	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	3.91e-05	0.000263	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	3.91e-05	0.000263	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.9e-05	0.000262	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	3.87e-05	0.000261	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—YAP1—polycystic ovary syndrome	3.86e-05	0.00026	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.81e-05	0.000257	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	3.8e-05	0.000255	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	3.76e-05	0.000253	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	3.73e-05	0.000251	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NAMPT—polycystic ovary syndrome	3.71e-05	0.00025	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	3.7e-05	0.000249	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.69e-05	0.000248	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP11A1—polycystic ovary syndrome	3.66e-05	0.000247	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	3.65e-05	0.000245	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	3.62e-05	0.000243	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	3.6e-05	0.000242	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	3.57e-05	0.00024	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	3.57e-05	0.00024	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	3.49e-05	0.000235	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—AKR1C3—polycystic ovary syndrome	3.46e-05	0.000233	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	3.43e-05	0.000231	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	3.41e-05	0.000229	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP17A1—polycystic ovary syndrome	3.41e-05	0.000229	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	3.4e-05	0.000229	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.36e-05	0.000226	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	3.33e-05	0.000224	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.31e-05	0.000223	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.26e-05	0.000219	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.24e-05	0.000218	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	3.23e-05	0.000217	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.19e-05	0.000215	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	3.17e-05	0.000214	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	3.16e-05	0.000212	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.14e-05	0.000211	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	3.06e-05	0.000206	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	3.03e-05	0.000204	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	3e-05	0.000202	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	3e-05	0.000202	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.97e-05	0.0002	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TH—polycystic ovary syndrome	2.95e-05	0.000198	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.93e-05	0.000197	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.93e-05	0.000197	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	2.92e-05	0.000196	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	2.89e-05	0.000195	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	2.89e-05	0.000195	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.89e-05	0.000194	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SLC2A4—polycystic ovary syndrome	2.87e-05	0.000193	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	2.86e-05	0.000193	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.86e-05	0.000193	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	2.83e-05	0.00019	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.83e-05	0.00019	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.8e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.79e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.78e-05	0.000187	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	2.74e-05	0.000184	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.73e-05	0.000184	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.72e-05	0.000183	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.71e-05	0.000182	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP19A1—polycystic ovary syndrome	2.7e-05	0.000181	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	2.66e-05	0.000179	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	2.64e-05	0.000178	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	2.64e-05	0.000178	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	2.62e-05	0.000177	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	2.62e-05	0.000176	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	2.6e-05	0.000175	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.58e-05	0.000174	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	2.58e-05	0.000174	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.57e-05	0.000173	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	2.56e-05	0.000172	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	2.52e-05	0.00017	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	2.5e-05	0.000168	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.48e-05	0.000167	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.47e-05	0.000166	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	2.44e-05	0.000164	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GNAS—polycystic ovary syndrome	2.41e-05	0.000162	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	2.35e-05	0.000158	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	2.32e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	2.3e-05	0.000155	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	2.3e-05	0.000155	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NCOR1—polycystic ovary syndrome	2.29e-05	0.000154	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	2.26e-05	0.000152	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.25e-05	0.000152	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.25e-05	0.000151	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	2.25e-05	0.000151	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	2.23e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	2.23e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.22e-05	0.000149	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.19e-05	0.000148	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP1A1—polycystic ovary syndrome	2.17e-05	0.000146	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	2.17e-05	0.000146	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	2.15e-05	0.000145	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	2.15e-05	0.000144	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.15e-05	0.000144	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	2.11e-05	0.000142	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	2.11e-05	0.000142	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	2.08e-05	0.00014	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	2.08e-05	0.00014	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	2.06e-05	0.000139	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	2.05e-05	0.000138	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.05e-05	0.000138	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	2.04e-05	0.000137	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—MTHFR—polycystic ovary syndrome	2.03e-05	0.000136	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.02e-05	0.000136	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.94e-05	0.000131	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.92e-05	0.000129	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.91e-05	0.000129	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.89e-05	0.000127	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.84e-05	0.000124	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.8e-05	0.000121	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.77e-05	0.000119	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.75e-05	0.000118	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.65e-05	0.000111	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.64e-05	0.000111	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PPARG—polycystic ovary syndrome	1.64e-05	0.000111	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TH—polycystic ovary syndrome	1.64e-05	0.00011	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—POMC—polycystic ovary syndrome	1.62e-05	0.000109	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—INS—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.61e-05	0.000108	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	1.59e-05	0.000107	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.58e-05	0.000106	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.55e-05	0.000104	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.54e-05	0.000104	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	1.52e-05	0.000102	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.51e-05	0.000102	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	1.51e-05	0.000101	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	1.5e-05	0.000101	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.49e-05	0.0001	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.49e-05	0.0001	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.47e-05	9.87e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.46e-05	9.82e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.46e-05	9.81e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.42e-05	9.53e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.4e-05	9.4e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.39e-05	9.32e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	1.35e-05	9.08e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	1.34e-05	9e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	1.32e-05	8.91e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	1.29e-05	8.65e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	1.27e-05	8.57e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	1.23e-05	8.31e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	1.22e-05	8.2e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	1.21e-05	8.13e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.14e-05	7.67e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.14e-05	7.64e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	1.13e-05	7.58e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.12e-05	7.51e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1e-05	6.74e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	9.88e-06	6.65e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—INS—polycystic ovary syndrome	9.82e-06	6.61e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.74e-06	6.55e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.53e-06	6.41e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	9.21e-06	6.2e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	9.13e-06	6.14e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	9.08e-06	6.11e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	9.03e-06	6.08e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	9.01e-06	6.06e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—INS—polycystic ovary syndrome	8.96e-06	6.03e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	6.74e-06	4.53e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	6.59e-06	4.43e-05	CbGpPWpGaD
